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Effect of converting enzyme inhibition on the course of adriamycin-
induced nephropathy. The effect of the converting enzyme inhibitor
(CE!) enalapril was assessed in Munich-Wistar rats with established
adriamycin nephrosis. Rats were given a single dose of adriamycin and
one month later divided into four groups matched for albuminuria,
blood pressure, and plasma albumin concentration. Groups 1 and 3
remained untreated while groups 2 and 4 received enalapril. Groups I
and 2 underwent micropuncture studies after 10 days. These short-term
studies showed that enalapril reduced arterial blood pressure (101 2
vs. 124 3 mm Hg, group 2 vs. I, P < 0.05) and glomerular capillary
pressure (54 I vs. 61 2 mm Hg, P < 0.05) without reducing
albuminuria (617 50 vs. 570 47 mg/day) or GFR (1.03 0.04 vs.
1.04 0.11 mI/mm). Groups 3 and 4 were studied at four and at six
months to assess the effect of enalapril on progression of renal injury in
adriamycin nephrosis. Chronic enalapril treatment reduced blood pres-
sure without reducing albuminuria in group 4. Untreated group 3 rats
exhibited a progressive reduction in GFR (0,35 0.08 mI/mm at 4
months, 0.27 0.07 ml/min at 6 months). Enalapril treatment blunted
but did not prevent reduction in GFR in group 4 (0.86 0.15 mI/mm at
4 months, 0.69 0.13 ml/min at 6 months, both P < 0.05 vs. group 3).
Reduction in GFR was associated with the development of glomerular
sclerosis in both treated and untreated rats. Enalapril treatment limited
but did not prevent glomerular sclerosis (sclerosis scores group 3 vs. 4:
29 5 vs. 10 Sat 4 months, P < 0.05; 54 5 vs. 37 8 at 6 months,P = NS). These results show that CE! treatment does not reduce
albuminuria and offers limited protection against progressive loss of
renal function in adriamycin nephrosis.
Recent studies have related progressive glomerular injury to
elevated glomerular capillary pressure in rats with reduced
nephron number and in rats with diabetes mellitus. Treatment
with a converting enzyme inhibitor has been shown to reduce
glomerular capillary pressure and to prevent development of
albuminuria and glomerular sclerosis in these two models of
renal disease [1—3]. Treatment with converting enzyme inhibi-
tors has also been shown to reduce albuminuria in rats with
passive Heymann nephritis [4]. The current study was designed
to assess the effect of converting enzyme inhibitor treatment in
rats with adriamycin-induced nephropathy. The glomerular
injury induced by adriamycin is characterized by sustained
heavy proteinuria and by glomerular capillary hypertension
[5—7]. Chronic studies have shown that heavy proteinuria is
associated with eventual development of widespread glomeru-
lar sclerosis and reduction of the glomerular filtration rate in
this disease model [8—10]. In the current study we sought first to
show whether administration of a converting enzyme inhibitor
would reduce glomerular capillary pressure and albuminuria in
rats with established adnamycin nephrosis. Second, we sought
to establish whether chronic treatment with a converting en-
zyme inhibitor would prevent development of glomerular scle-
rosis and renal insufficiency in this model of the nephrotic
syndrome.
Methods
Male Munich-Wistar rats weighing 226 to 258 grams received
a single dose of adriamycmnR (doxorubicin HC1), 3.3 mg/kg, via
tail vein injection under brevital anesthesia. Previous studies
have shown that heavy proteinuria is established four weeks
after administration of adnamycin [5, 61. Baseline measure-
ments were therefore obtained at this time point, and the
nephrotic rats were divided into four groups with similar mean
values for systolic blood pressure, urinary albumin excretion
rate, and plasma albumin concentration. Groups 1 and 3 there-
after received no specific therapy while groups 2 and 4 were
given the converting enzyme inhibitor enalapril, 400 mg/liter in
the drinking water. All animals had unrestricted access to
standard rat chow containing —24% protein by weight.
Short-term effect of converting enzyme inhibition
The short-term effect of converting enzyme inhibition in rats
with established adriamycin nephrosis was assessed in un-
treated group 1 rats (N = 8) and enalapril-treated group 2 rats
(N = 8). Repeat measurements of albumin excretion rate, blood
pressure, and plasma albumin concentration were obtained 10
days after baseline. Following these measurements, micropunc-
ture studies were performed to relate the effect of CE! treat-
ment on albuminuria and blood pressure to its effect on glomer-
ular hemodynamic function.
Micropuncture studies
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Rats were anesthetized with mactin, 70 mg/kg intraperitone-
ally, and placed on a temperature-regulated micropuncture
table. A PESO catheter was inserted into the left femoral artery
to obtain arterial blood samples and record mean arterial
pressure (AP). A was continuously monitored with an elec-
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tronic pressure transducer connected to a direct-writing pres-
sure recorder. After tracheostomy, PESO catheters were in-
serted into the jugular veins for infusion of rat plasma, inulin,
and saline, and the left ureter was catheterized with PE1O
tubing. After insertion of the jugular catheters, plasma was
infused in an amount equal to 1% body weight over 40 to 45
minutes, followed by an infusion of —0.5 mllhr for the duration
of the experiment. Plasma for infusion was obtained by mixing
aliquots of plasma from nephrotic donor rats and normal donor
rats to provide an albumin concentration equal to that of the
animal being studied. Nephrotic donor rats were Sprague-
Dawley rats given adriamycin, 3 mglkg i.v., four weeks prior to
sacrifice. Saline was infused in an amount equal to 4% body
weight over 80 to 110 minutes followed by a reduction in
infusion rate to 2.4 mI/hr for the remainder of each experiment.
At this point tritiated methoxy-inulin was added to the saline to
obtain an infusion rate of —110 CiIhr following a loading dose
of—SO mCi.
Micropuncture studies were then carried out during two to
three 30- to 40-minute clearance periods. In each period a 200 jsl
arterial blood sample was drawn for determination of arterial
hematocrit (Hct) and plasma inulin and total protein concentra-
tion. A simultaneous 100 d blood sample was obtained from an
indwelling left renal vein catheter to determine filtration frac-
tion by comparison of arterial and renal vein inulin concentra-
tions. Time averaged hydraulic pressure measurements were
obtained in surface glomerular capillaries (2 to 4 determinations
per rat), proximal tubules (3 to 7 determinations), and efferent
arterioles (3 to 4 determinations) with a continuous recording
servo-null micropipette transducer system (Model V. Instru-
mentation for Physiology and Medicine, San Diego, California,
USA) coupled to the second channel of the pressure recorder.
Timed (4 mm) samples of tubule fluid were obtained from
superficial proximal tubules of three to five nephrons to deter-
mine the single nephron glomerular filtration rate (SNGFR).
The pressor responses to 25, 50, 100 and 200 ng i.v. bolus doses
of angiotensin I were measured following micropuncture study
to verify effective converting enzyme inhibition in enalapril-
treated rats.
Chronic effect of converting enzyme inhibition
The effect of converting enzyme inhibition on the course of
adriamycin-induced nephropathy was assessed in untreated
group 3 rats (N = 26) and enalapril-treated group 4 rats (N =
21). In this chronic study the dose of enalapril was increased to
600 mg/liter in two rats after one month and to 500 mg/liter in
four rats after four months. Repeat measurements of systolic
blood pressure and albuminuria were obtained bimonthly. In
approximately half of these rats (N = 10 group 3 rats and N =
9 group 4 rats) glomerular filtration rate was measured and
kidney tissue obtained for morphologic analysis after four
months. Similar studies were performed in the remaining ani-
mals after six months.
Functional studies. Rats were prepared as described for
micropuncture studies. Glomerular filtration rate was measured
over two 30-minute clearance periods. GFR was not measured
in two group 3 rats studied at six months.
Morphologic studies. Following measurement of the GFR,
kidneys were fixed by retrograde aortic perfusion at measured
arterial pressure with 1.25% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4). After perfusion fixation, the weight
of the left kidney was measured and two 2 mm thick coronal
sections through the midportion of the kidney were post-fixed in
buffered 4% formaldehyde solution. Paraffin sections were
stained by the Periodic Acid Schiff technique and with hema-
toxylin and eosin. A modification of the scoring system of Raij,
Azar and Keane [111 was used to evaluate the degree of
glomerular injury in each animal. Each glomerulus in a single
section was assigned a score from 0 to 3+ according to the
portion of the tuft manifesting sclerotic changes. A score of 0
was assigned to glomeruli without sclerotic changes, a score of
1 to glomeruli with less than one-third of the tuft showing
sclerotic changes, a score of 2 to glomeruli with between
one-third and two-thirds of the tuft showing sclerotic changes,
and a score of 3 to glomeruli with sclerotic changes in all areas
of the tuft. The glomerular injury score for each animal was
then calculated as:
F,.
Score =
I —
03
where F1 is the percentage of glomeruli in that animal with a
given score i. This analysis was performed on an average of 120
glomeruli per animal.
Analytical. Systolic blood pressure was obtained by the tail
cuff method. Urine and plasma albumin concentrations were
measured by rate nephelometry (Beckman Immunochemistry
Analyzer II, Beckman Instruments, Palo Alto, California,
USA) utilizing specific anti-rat albumin (Cappel Diagnostics,
Malvern, Pennsylvania, USA). Plasma total protein concentra-
tion was measured with a Lowry assay modified to prevent
interference by plasma lipids [12]. The inulin content of plasma,
urine, and tubule fluid was assessed by liquid phase scintillation
counting.
Calculations. Efferent arteriolar protein concentration (CE)
was calculated from the afferent arteriolar protein concentra-
tion (CA) and the filtration fraction (if) as:
CACE =
A recently derived set of equations relating oncotic pressure to
plasma protein concentration in nephrotic rats was used to
calculate plasma oncotic pressure [13]. A standard mathemati-
cal model was used to derive the glomerular capillary ultrafil-
tration coefficient, K, and single afferent and efferent arteriolar
resistances from these values for oncotic pressure and from
measured parameters [14].
The statistical significance of differences in values of individ-
ual parameters in the groups was evaluated by unpaired t-test
when two groups were compared and by ANOVA when more
than two groups were compared (comparisons of 4- and 6-
month values in groups 3 and 4). Comparison of blood pressure
and albumin excretion rate at different time points in the same
group was made by paired t-test. Significance was defined as P
<0.05 and results are expressed as mean 1 SEM throughout.
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Table 1. Summary of renal cortical microcirculation studies
Body
wt
g
Hct
%
AP
mm
Hg
UNaV
sEq/
mm
GFR
ml!
mm
SNGFR
ni/mm ff
Qa
nil
mm
GC 1T 1E CA CE
mm Hg gIdi
Group 1
N = 8
Group 2
N = 8
264
272
42
42
122
ioia
1,07
0.71
1.04
1.03
42
40
0.27
0.23
157
168
61
54
13 15
13 13
49
42
4.9
4.6
6.8
6.1
Mean values are SEM. Abbreviations used in this table are: wt, weight; Hct, hematocrit; AP, mean arterial pressure; UNaV, urine sodium
excretion during micropuncture study; GFR, glomerular filtration rate; SNGFR, single nephron glomerular filtration rate; if, filtration fraction; QA,
single nephron plasma flow rate; P, mean glomerular capillary hydraulic pressure; T, proximal tubule hydraulic pressure; P, efferent arteriolar
hydraulic pressure; P, mean glomerular transcapillary hydraulic pressure gradient; CA and CE, aiferent and efferent artenolar plasma protein
concentration; ITA and ITE, aiferent and efferent arteriolar colloid osmotic pressure; RA and RE, aiferent and efferent arteriolar resistance; RT, total
arteriolar resistance; Kf, glomerular capillary ultrafiltration coefficient.
a Values for CEI different from Control, P < 0.05.
Results
Short-term effect of converting enzyme inhibition
Systemic blood pressure. The effect of 10 days of converting
enzyme inhibitor treatment on systolic blood pressure in ne
phrotic rats is depicted in Figure 1. Baseline systolic blood
pressure averaged 134 mm Hg in group 2 and 133 3 mm
Hg in group 1. CE! treatment reduced systolic blood pressure to
106 2 mm Hg (P < 0.05). Systolic blood pressure was stable
in the untreated nephrotic rats and averaged 135 6 mm Hg at
10 days,
Urinary albumin excretion rate. The effect of 10 days of
converting enzyme inhibitor treatment on urinary albumin
excretion rate (UaIbV) in nephrotic rats is depicted in Figure 2.
Baseline albuminuria averaged 617 49 mg/day in group 2 and
610 20 mg/day in group 1. Urinary albumin excretion rate was
not reduced after 10 days of CE! treatment despite marked
reduction in systemic blood pressure. Urinary albumin excre-
tion rate likewise remained stable in untreated nephrotic rats.
Mean plasma albumin concentration also did not change signif-
icantly in either group over the course of the short-term
experiment. Baseline plasma albumin concentration averaged
1.1 0.2 g/dl in both groups. At 10 days plasma albumin
concentration averaged 1.2 0.2 g/dl in group 2 and 1.0 0.2
g/dl in group 1.
Micropuncture studies. Mean values for body weight, Hct,
arterial pressure (AP), left kidney GFR, SNGFR, and the
pressures, flows and resistances governing glomerular ultrafil-
tration in rats in the short-term study are summarized in Table
1. Mean values for body weight and hematocrit were equivalent
in the two groups. Mean arterial pressure AF in untreated
nephrotic rats averaged 122 3 mm Hg, whereas the mean
arterial pressure in the enalapril-treated rats was significantly
lower, averaging 101 2 mm Hg (P <0.05). Despite reduction
in renal perfusion pressure, whole kidney GFR was similar in
the two groups of nephrotic rats, averaging 1.04 0.11 mI/mm
in untreated animals and 1.03 0.04 mI/mm in the enalapril-
treated nephrotic animals.
Like whole kidney GFR, values for single nephron glomeru-
lar filtration rate (SNGFR) were similar in the two experimental
groups, averaging 42 3 nI/mm in untreated nephrotic rats and
40 4 ru/mm in enalapril-treated rats. Values for single nephron
plasma flow rate, QA' did not differ in the two groups, averaging
157 10 nllmin in untreated rats and 168 16 nI/mm in
150-
140-
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120
110
100
1000
900
800
700
600
500
0
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Fig. 1. Systolic blood pressure (SBP) in nephrotic rats studied over 10
days. Blood pressure in untreated group 1 rats (0) remained stable,
while enalapril-treated group 2 rats (U) exhibited reduction of blood
pressure. Values are mean I sa. ap < 0.05 vs. baseline measurement,
bp < 0.05 vs. untreated rats.
I I
Baseline 10 days
400
300
200
Baseline 10 days
Fig. 2. Urinary albumin excretion rate (UalbV) in nephrotk rats stud-
ied over 10 days. Urinary albumin excretion remained stable in both
untreated group 1 rats (El) and enalapril-treated group 2 rats (U).
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Table 1. Extended
E
mmHg
RA RE RT Kfni/s mm
Hgdyne.s.cm
11.7 20.2 1.96 1.91 3.87 0.022
10.8 17.1 1.47 1.51 2.98 0.023
enalapril-treated rats. The glomerular transcapillary hydraulic
pressure difference, zP, averaged 49 2 mm Hg in untreated
nephrotic rats. The finding of a high value for zP in rats with
untreated adriamycin nephrosis is similar to that of O'Donnell
et al [7] but different from that of Fogo et al [10]. In the present
study, converting enzyme inhibitor therapy lowered zP to 42
1 mm Hg, a value only slightly above that obtained in normal
rats in our laboratory [15]. The reduction in zP seen with
enalapril resulted from a fall in the mean glomerular capillary
hydraulic pressure (Gc), as values for proximal tubule hydrau-
lic pressure were similar in the two groups. Values for oncotic
pressure in afferent arteriolar plasma were also similar in the
two groups, averaging 11.7 1.0 mm Hg in untreated rats and
10.8 0.8 mm Hg in enalapril-treated rats. Maintenance of
single nephron plasma flow rate despite reduction in mean
arterial pressure in enalapril-treated rats indicates that convert-
ing enzyme inhibitor therapy caused arteriolar vasodilatation in
the nephrotic kidney. Calculated values for afferent arteriolar
resistance (RA) and efferent arteriolar resistance (RE) were
lower in enalapril-treated rats, but these differences did not
reach statistical significance. Values for the glomerular capil-
lary ultrafiltration coefficient (Kf) also did not differ significantly
between the two groups.
The effectiveness of converting enzyme inhibition was con-
firmed by measuring the pressor response to graded boluses of
angiotensin I at the close of the micropuncture studies. Figure
3 illustrates the marked reduction in pressure response to
angiotensin I observed in enalapril-treated rats.
Chronic effect of converting enzyme inhibition
Survival. Untreated group 3 nephrotic rats had a higher
mortality than enalapril-treated group 4 rats, but this difference
was not significant by chi-square analysis. In group 3, 5 of 26
rats did not survive for four months and two more rats died
before six months. In group 4, 3 of 21 rats did not survive for
four months. Values for albuminuria and systolic blood pres-
sure in these animals were excluded from analysis.
Systemic blood pressure. As described by Okuda et al [8],
rats with untreated chronic adriamycin-induced nephropathy
exhibited a rise in systolic blood pressure (Fig. 4). Baseline
systolic blood pressure in this group averaged 145 3 mm Hg
and rose significantly to a mean value of 165 6 mm Hg at four
months and a value of 162 5 mm Hg at six months. Systolic
blood pressure was significantly lower at each time point in the
enalapril-treated nephrotic rats.
Urinary albumin excretion rate. The effect of chronic con-
verting enzyme inhibitor treatment on albumin excretion rate is
depicted in Figure 5. The mean albumin excretion rate in
untreated animals was 603 21 mg/day at baseline and rose to
817 43 mg/day at four months and 819 62 mg/day at six
months. Despite sustained reduction of blood pressure, enala-
pril-treated nephrotic rats showed a similar rise in urinary
albumin excretion during the study. Albumin excretion rate in
this group averaged 589 28 mg/day at baseline and rose to 747
51 mg/day at four months and 773 107 mg/day at six
months.
Renal function. Table 2 shows values obtained in groups 3
and 4 at the close of the study. Mean values for body weight
were slightly but not significantly greater in the treated rats.
Values for serum albumin concentration were similar in each
group. As expected, mean arterial pressure in enalapril-treated
group 4 rats was reduced significantly below the values ob-
served in untreated group 3 rats at both four and six months.
Chronic adriamycin nephropathy in both untreated group 3 rats
and in treated group 4 rats was associated with a reduction in
glomerular filtration rate as compared to values obtained in
group 1 and 2 rats studied earlier in the disease course. In group
3 rats the glomerular filtration rate averaged 0.35 0.08 mI/mm
at four months and 0.27 0.07 mllmin at six months as
compared to the value of 1.04 0.11 mI/mm obtained in group
1 (P < 0.05 both intervals). Sustained reduction of blood
pressure with enalapril limited but did not prevent reduction in
glomerular filtration rate. The glomerular filtration rate in group
4 averaged 0.86 0.15 ml/min at four months and 0.68 0.13
mllmin at six months. These values were significantly greater
than the values for GFR in untreated group 3 rats at both time
intervals but lower than the GFR value of 1.03 0.04 mI/mm
obtained in group 2 (P < 0.05 vs. group 2 only at 6 months).
Structural alterations. Both untreated and enalapril-treated
adriamycin nephrotic rats developed glomerular sclerosis at
four and six months, with higher sclerosis scores at six months
suggesting progression of glomerular injury with time (Table 2).
Partial preservation of GFR in enalapril-treated group 4 rats
was associated with lower glomerular sclerosis scores in this
group. The reduction in sclerosis score achieved statistical
significance at four months (10 5 vs. 29 5, group 4 vs. group
3, P < 0.05) but not at six months (37 8 vs. 54 5, group 4
E
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60
40
20
b
0 50 100 150 200 250
Angiotensin I, ng
Fig. 3. Pressor response (LMAP) to bolus infusions of angiotensin I in
untreated (El) and enalapril-treated (•) nephrotic rats undergoing
micropuncture study. The pressor response was markedly attenuated in
enalapril-treated rats. bp < 0.05 vs. untreated rats.
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vs. group 3). Widespread tubulointerstitial changes consisting
of tubule dilatation, atrophy, intratubular cast formation, and
interstitial fibrosis and inflammation accompanied glomerular
sclerotic injury in both groups. The extent of this tubulointer-
stitial injury was not quantified, but appeared to correlate with
the extent of glomerular sclerosis.
Discussion
Recent studies have shown that treatment with a converting
enzyme inhibitor to reduce systemic and glomerular capillary
pressure largely prevents development of albuminuria and
glomerular sclerosis in rats with reduced renal mass and rats
with diabetes mellitus [1—3]. The object of the current study was
to assess the effect of converting enzyme inhibitor treatment on
the course of renal disease in rats with glomerular injury
characterized by heavy proteinuria. Glomerular injury was
induced by a single dose of adriamycin, as described by Bertani
and coworkers [5, 161. These investigators have shown that
adriamycin, though it has a short half-life, causes irreversible
glomerular injury manifested by proteinuria which remains
stable over several months.
The initial goal of the current study was to determine whether
converting enzyme inhibitor treatment would reduce albumin-
uria in rats with adriamycin nephrosis. It has recently been
suggested that maneuvers which reduce glomerular capillary
pressure can reduce permeability to macromolecules in injured
glomeruli. In accord with this hypothesis, Yoshioka et al [17]
found that acute infusion of acetylcholine reduced both glomer-
ular capillary pressure and protein excretion rate in rats with
passive Heymann nephritis. More recently, Hutchison, Scham-
belan and Kaysen [4] have shown that sustained treatment with
converting enzyme inhibitors reduces albuminuria in this dis-
ease model. Results of the current study indicate, however, that
treatment with the converting enzyme inhibitor enalapnl does
not reduce albuminuria in rats with adriamycin nephrosis.
Albumin excretion rate remained stable in rats treated with
enalapril for 10 days despite significant reduction of both
systemic and glomerular capillary pressure.
0- I I I
Baseline 2 months 4 months 6 months
Fig. 5. Urinary albumin excretion rate (U,bV) in nephrotic rats fol-
lowed for 6 months. Both untreated group 3 rats (0) and enalapril-
treated group 4 rats (•) exhibited a progressive rise in urinary albumin
excretion over the 6 month study. ap < 0.05 vs. baseline measurement.
Results of the current short-term study are consistent with
the preliminary results of Beukers, Hoedemaeker and Weening
[181 showing that captopril treatment does not reduce protein-
uria in rats with adriamycin nephrosis. The reason why con-
verting enzyme inhibition reduces proteinuria in passive Hey-
mann nephritis but not in adriamycin nephrosis is unclear. This
apparent difference in drug effect cannot be accounted for by
differing duration of experimental treatment. Hutchison et al
[19] have shown that the decrement in proteinuria observed in
rats with Heymann nephritis given enalapril increases over 14
days of drug treatment. In contrast, the current results along
with those of Beukers et al [181 indicate that proteinuria in rats
with adriamycin nephrosis is not reduced by treatment with
converting enzyme inhibitors over periods ranging from eight
days to many weeks. Together, these studies suggest that use of
converting enzyme inhibitors to lower glomerular capillary
pressure cannot be expected to reduce protein excretion in
every form of glomerular injury. Of note, available clinical
studies indicate that converting enzyme inhibitor therapy low-
ers proteinuria in some but not all nephrotic patients [20—23].
The second goal of the current study was to assess the effect
of sustained converting enzyme inhibitor treatment on progres-
sion of glomerular injury in rats with adriamycin nephrosis.
Morphologic studies carried out at 4 to 12 weeks after admin-
istration of adriamycin initially suggested that adriamycin-
induced glomerular injury does not proceed to glomerular
sclerosis [5, 6, 24]. More prolonged studies, however, have
since established that rats with adriamycin nephrosis develop
widespread glomerular sclerosis over a period of seven to nine
months [8—10]. Okuda et al [8] have shown that progressive
glomerular sclerosis in this model is associated with a decline in
the glomerular filtration rate and with spontaneous develop-
ment of hypertension. Results in rats maintained without treat-
ment for five and seven months after adriamycin injection in the
current study are consistent with these findings. These rats
exhibited elevation of systemic blood pressure and reduction of
the GFR associated with a glomerular sclerosis score which
reflected sclerotic lesions in the majority of glomeruli. Convert-
a
a
180
170
160
150
140
130
120
110
1200
1000
800-
E 600
400-
200 -
aa
E
0
a)
Fig. 4. Systolic blood pressure (SBP) in nephrotic rats followed for 6
months. Untreated group 3 rats (0) showed a progressive rise in blood
pressure. Enalapril-treated group 4 rats (U) exhibited significantly
lower systolic blood pressure throughout the study. ap < 0.05 vs.
baseline measurement, bp < 0.05 vs. untreated rats.
I I I I
Baseline 2 months 4 months 6 months
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Table 2.
Months
Body
wt
g
AIb
gidi
AP
mm
Hg LKW
GFR
mi/mm SS
Group 3 4 303 1.3 141 1.71 0.35 29
N = 10
Group3c 6 314 1.4 140 1.93 0.27 54bN = 9
Group 4 4 331 1.4 iiia 2.01 0.86a ioa
N = 9
Group 4 6 343 1.3 112k 2.02 0.68a 37b
N = 9
Mean values SCM. Abbreviationsare: Aib, serum albumin concen-
tration; AP, mean arterial pressure; GFR, glomerular filtration rate;
LKW, left kidney weight; SS, sclerosis score
a P < 0.05, group 4 vs. group 3 at the same time intervalb P < 0.05, 6-month value vs. 4-month value for the same group
GFR values were not obtained in two group 3 rats at 6 months
ing enzyme inhibitor treatment lowered blood pressure and
blunted but did not prevent progressive loss of glomerular
function in rats with adriamycin nephrosis. The average values
for GFR were significantly higher in enalapril treated than in
untreated nephrotic rats in our chronic study. However, the
values for GFR in both the treated and untreated rats at seven
months after adriamycin administration in the chronic study
were lower than the values for GFR obtained six weeks after
adriamycin administration in the short-term study.
In the present study, reduction of GFR in untreated rats with
chronic adriamycin nephrosis was associated with development
of widespread glomerular sclerosis, while partial preservation
of GFR in enalapril-treated rats was associated with develop-
ment of less extensive glomerular sclerosis. These associations
do not establish that glomerular sclerosis per se is the sole
mechanism responsible for reduction of GFR in chronic adri-
amycin nephrosis. Rats with chronic adriamycin nephrosis also
exhibited extensive tubulointerstitial injury. This injury was not
quantified in the current study, but could certainly contribute to
the reduction in GFR observed in these animals.
Results of the current study show that converting enzyme
inhibitor therapy offers only limited protection against progres-
sive loss of renal function in rats with adriamycin nephrosis.
This finding contrasts with previous results in rats with reduced
nephron number and rats with diabetes mellitus, in which
converting enzyme inhibitor therapy largely prevented devel-
opment of glomerular sclerosis [1—3]. The current study sug-
gests that factors other than glomerular capillary hypertension
make a major contribution to the progression of renal injury in
adriamycin nephrosis. One factor which may contribute to
progressive renal injury in nephrosis is persistent heavy pro-
teinuria. Of note, CEI therapy afforded less protection against
late glomerular sclerosis in our rats with adriamycin nephrosis
than was observed by Anderson et al [25] in a study of rats with
puromycin nephrosis. In that study, rats were given a single
injection of puromycin in order to induce transient heavy
proteinuria. Late development of glomerular sclerosis was
attributable to sustained elevation of glomerular capillary pres-
sure following remission of the initial proteinuria. In contrast,
we assessed the development of glomerular sclerosis in ne-
phrotic rats with persistent heavy proteinuria. In this regard,
our results are comparable to those of Fogo et al [10] who have
shown that progressive glomerular sclerosis develops despite
maintenance of normal glomerular capillary pressure in rats
with persistent proteinuria induced by repeated injection of
puromycin. These investigators have further shown that partial
protection against the development of progressive glomerular
sclerosis by CEI treatment cannot be attributed to reduction of
glomerular capillary pressure in this disease model.
The mechanisms responsible for progressive renal injury
associated with persistent heavy proteinuria remain to be
elucidated. Bertani et al [26] have suggested that heavy protein-
uria leads to cast formation with tubular obstruction and
subsequent tubulo-interstitial injury. It has further been sug-
gested that the alterations in glomerular capillary wall perme-
ability characteristics which cause proteinuria also promote
gradual accumulation of subendothelial hyaline material. Such
accumulation is frequently observed in areas of segmental
sclerosis and may contribute to the development of glomerular
sclerotic injury. Either of these mechanisms could contribute to
progressive loss of renal function and glomerular injury when
albumin excretion rate remains high, despite reduction of
systemic and glomerular capillary pressure by converting en-
zyme inhibitor treatment.
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